![Page 1: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/1.jpg)
Updated Guidelines for Management of Candidiasis
Vidya Sankar, DMD, MHSApril 6, 2017
![Page 2: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/2.jpg)
Statement of DisclosureI have no actual or potential conflict of interest in
relation to this presentation
![Page 3: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/3.jpg)
Outline
• Review mechanisms of antifungal drugs• Present Infectious Disease Society of America
Clinical Practice Guidelines for the Management of Candidiasis
• Emphasis on treatment for oropharyngeal candidiasis
• Development of resistance
![Page 4: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/4.jpg)
Introduction
• Invasive fungal infections– 1.5 million deaths worldwide each year– 30-40% mortality for invasive candidiasis– 20-30% for cryptococcosis– 20-30% for aspergillosis
• Mucosal and skin– Candida
• 4th nosocomial infections• C. glabrata
![Page 5: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/5.jpg)
Antifungal Drugs
Taken and adapted from: Mechanisms in Medicine
![Page 6: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/6.jpg)
Antifungal DrugsAzoles
fungistatic
![Page 7: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/7.jpg)
Antifungal DrugsAzoles
Imidazoles: Clotrimizole, miconazole, ketaconazoleTriazoles: Fluconazole, itraconzole
Voriconazole, posiconazole, isavuconazole
![Page 8: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/8.jpg)
Antifungal DrugsPolyenes
fungicidal
![Page 9: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/9.jpg)
Antifungal DrugsEchinocandins
FungistaticCaspofunginMucofunginAndulofungin
![Page 10: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/10.jpg)
![Page 11: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/11.jpg)
Background
• HIV infection, diabetes, steroid, leukemia, RT and antimicrobial therapy
• Dramatic decline (antiretroviral therapy)• Fluconazole or multiazole resistance or
emergence of non-albicans species – Repeated – Long-term exposure
• Symptomatic relapse to topical therapy– Sooner– More frequently
![Page 12: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/12.jpg)
Candidemia
2016 2009
Initial EchinocandinC 70 mg/50 mgM 100 mgA 200 mg/100 mg
Fluconazole 800/400Echinocandins (neutropenic)
Alternative Fluconazole 800/400mg
Transition Fluconazole (5-7 d)
C. GlabrataAzole resistantEchinocandin resistant
AmB lipid formulation Echinocandin
Transition Fluconazole 800 mgVoriconazole 2-300 BID
![Page 13: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/13.jpg)
1st Line Alternative 2009
Mild Clotrimozole 10mg 7-14dMiconazole 50 mg QD
Nystatin suspension Nystatin pastilles
Clotrimazole
Moderate Fluconazole 100-200 7-14 d Fluconazole
Refractory Itraconazole soln 200mg QDPosiconazole sus 400mg BID (3 d then QD up to 28 d)
Voriconazole 200mg BIDAmB oral 100mg/mLQIDIV echinocandin or AmB*
Same initial therapy
Chronic Suppressive
Fluconazole 100 mg 3x/week
Fluconazole 100 mg 3x/week
Denture Disinfection
Oropharyngeal Candidiasis
![Page 14: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/14.jpg)
![Page 15: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/15.jpg)
Esophageal2016 2009
Initial Fluconazole 200-400 mg 14-21 d
Alternative IV FluconazoleEchinocandinAmBItraconazole
Also: Posaconazole
Refractory ItraconazoleVoriconazoleEchinocandins
Suppressive Fluconazole 100-200 mg 3x/week
![Page 16: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/16.jpg)
Drug Resistance
• Efflux pumps– ATP-binding cassette
proteins– Major facilitator
superfamily
• ERG11 overexpression• Erg3 Mutations• FKS1 gene mutation• Biofilms
![Page 17: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/17.jpg)
Drug Resistance • Efflux pumps
– Major facilitator superfamily
– ATP-binding cassette proteins
• ERG11 – Overexpression– Change in drug target
• Erg3 Mutations• FKS1 gene mutation• Biofilms
![Page 18: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/18.jpg)
Drug Resistance • Efflux pumps
– Major facilitator superfamily
– ATP-binding cassette proteins
• ERG11 – Overexpression– Change in drug target
• Erg3 Mutations• FKS1 gene mutation• Biofilms
Whaley SG et al. Front Microbiol 2017Campoy S et al. Biochem Pharm 2016
![Page 19: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/19.jpg)
Drug Resistance • Efflux pumps
– ATP-binding cassette proteins
– Major facilitator superfamily
• ERG11 – Overexpression– Change
• Erg3 Mutations• FKS1 gene mutation• Biofilms
Whaley SG et al. Front Microbiol 2017
![Page 20: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/20.jpg)
Drug Resistance
• Efflux pumps– ATP-binding cassette
proteins– Major facilitator
superfamily
• ERG11 overexpression• Erg3 Mutations• FKS1 gene mutation• Biofilms
Campoy S, Adrio JL Biochem Pharm 2016
![Page 21: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/21.jpg)
Drug Resistance • Efflux pumps
– ATP-binding cassette proteins– Major facilitator superfamily
• ERG11 overexpression• Erg3 Mutations• FKS1 gene mutation• Biofilms
– Hydrolytic enzymes– Surfactants– Chelating agents– Biocides
Baker JL et al. Trends Microbiol 2017
![Page 22: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/22.jpg)
In the PipelineCandida Infections
Β-glucan synthesis SCY-078 Phase 2
Biafungin Phase 2 *longer t1/2
Mitochondrial function T 2307 Phase 1
Carbon metabolismbiofilm synthesis
AR-12 Orphan drug
Azole Isavuconazole
![Page 23: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/23.jpg)
THANK YOU
![Page 24: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/24.jpg)
Esophageal Candidiasis
Fluconazole tablets 200 – 400 mg 14-21 d
IV fluconazoleEchinocandin
micofungincaspofunginanidulafungin
400 mg
150 mg QD70/50 mg200 mg QD
AmB deoxycholate
Itraconazole solution Voriconazole (IV or oral)
200 mg daily200 mg twice daily
14–21
Recurrent Infection: Fluconazole
100-200 mg tablets 3 X week
![Page 25: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/25.jpg)
![Page 26: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/26.jpg)
Antifungal Drugs
Glucan synthasecomplex
![Page 27: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/27.jpg)
C. Albicans C. glabrata C. krusei C. tropicalis C. parapsilosis
Fluconazole ++ - - - -
Itraconazole + + +
Voriconazole + - +
Posiconazole
Ketoconazole
Miconazole
Caspofungin ++ ++
Micafungin ++ ++
Anidulafungin ++ ++
AmB ++ ++ ++ ++ ++
Nystatin +
Coverage
![Page 28: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/28.jpg)
![Page 29: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/29.jpg)
![Page 30: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/30.jpg)
![Page 31: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/31.jpg)
![Page 32: Updated Guidelines for Management of Candidiasis€¦ · Oropharyngeal Candidiasis. Esophageal 2016. 2009: Initial. Fluconazole 200-400 mg 14-21 d: Alternative. IV Fluconazole: Echinocandin](https://reader034.vdocuments.net/reader034/viewer/2022050204/5f57c06582b7a756c80fbbe4/html5/thumbnails/32.jpg)